Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

被引:88
作者
Boj, Sylvia F. [1 ]
Vonk, Annelotte M. [2 ]
Statia, Marvin [1 ]
Su, Jinyi [1 ]
Vries, Robert R. G. [1 ]
Beekman, Jeffrey M. [2 ]
Clevers, Hans [1 ,3 ]
机构
[1] Fdn Hubrecht Organoid Technol, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Regenerat Med Ctr Utrecht, Dept Pediat Pulmonol, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Hubrecht Inst Dev Biol & Stem Cell Res, Utrecht, Netherlands
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2017年 / 120期
关键词
Medicine; Issue; 120; human colorectal organoids; primary cell culture; biopsy; cystic fibrosis; organoid swelling; CFTR function; Forskolin; Ivacaftor (VX-770); Lumacaftor (VX-809); TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR POTENTIATOR; STEM-CELLS; IVACAFTOR; LUMACAFTOR; MUTATION; DISEASE; MODEL;
D O I
10.3791/55159
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recently-developed cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs correct surface expression and/or function of the mutant CFTR channel in subjects with cystic fibrosis (CF). Identification of subjects that may benefit from these drugs is challenging because of the extensive heterogeneity of CFTR mutations, as well as other unknown factors that contribute to individual drug efficacy. Here, we describe a simple and relatively rapid assay for measuring individual CFTR function and response to CFTR modulators in vitro. Three dimensional (3D) epithelial organoids are grown from rectal biopsies in standard organoid medium. Once established, the organoids can be bio-banked for future analysis. For the assay, 30-80 organoids are seeded in 96-well plates in basement membrane matrix and are then exposed to drugs. One day later, the organoids are stained with calcein green, and forskolin-induced swelling is monitored by confocal live cell microscopy at 37 degrees C. Forskolin-induced swelling is fully CFTR-dependent and is sufficiently sensitive and precise to allow for discrimination between the drug responses of individuals with different and even identical CFTR mutations. In vitro swell responses correlate with the clinical response to therapy. This assay provides a cost-effective approach for the identification of drug-responsive individuals, independent of their CFTR mutations. It may also be instrumental in the development of future CFTR modulators.
引用
收藏
页数:12
相关论文
共 33 条
  • [1] Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
    Accurso, Frank J.
    Rowe, Steven M.
    Clancy, J. P.
    Boyle, Michael P.
    Dunitz, Jordan M.
    Durie, Peter R.
    Sagel, Scott D.
    Hornick, Douglas B.
    Konstan, Michael W.
    Donaldson, Scott H.
    Moss, Richard B.
    Pilewski, Joseph M.
    Rubenstein, Ronald C.
    Uluer, Ahmet Z.
    Aitken, Moira L.
    Freedman, Steven D.
    Rose, Lynn M.
    Mayer-Hamblett, Nicole
    Dong, Qunming
    Zha, Jiuhong
    Stone, Anne J.
    Olson, Eric R.
    Ordonez, Claudia L.
    Campbell, Preston W.
    Ashlock, Melissa A.
    Ramsey, Bonnie W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (21) : 1991 - 2003
  • [2] A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
    Boyle, Michael P.
    Bell, Scott C.
    Konstan, Michael W.
    McColley, Susanna A.
    Rowe, Steven M.
    Rietschel, Ernst
    Huang, Xiaohong
    Waltz, David
    Patel, Naimish R.
    Rodman, David
    [J]. LANCET RESPIRATORY MEDICINE, 2014, 2 (07) : 527 - 538
  • [3] Modeling Development and Disease with Organoids
    Clevers, Hans
    [J]. CELL, 2016, 165 (07) : 1586 - 1597
  • [4] Cystic fibrosis genetics: from molecular understanding to clinical application
    Cutting, Garry R.
    [J]. NATURE REVIEWS GENETICS, 2015, 16 (01) : 45 - 56
  • [5] Progress in therapies for cystic fibrosis
    De Boeck, Kris
    Amaral, Margarida D.
    [J]. LANCET RESPIRATORY MEDICINE, 2016, 4 (08) : 662 - 674
  • [6] Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
    De Boeck, Kris
    Munck, Anne
    Walker, Seth
    Faro, Albert
    Hiatt, Peter
    Gilmartin, Geoffrey
    Higgins, Mark
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (06) : 674 - 680
  • [7] Dekkers J. F., 2016, EUR RESP J
  • [8] Dekkers J. F., 2016, J CYST FIBROS
  • [9] Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
    Dekkers, Johanna F.
    Berkers, Gitte
    Kruisselbrink, Evelien
    Vonk, Annelotte
    de Jonge, Hugo R.
    Janssens, Hettie M.
    Bronsveld, Inez
    de Graaf, Eduard A. van
    Nieuwenhuis, Edward E. S.
    Houwen, Roderick H. J.
    Vleggaar, Frank P.
    Escher, Johanna C.
    de Rijke, Yolanda B.
    Majoor, Christof J.
    Heijerman, Harry G. M.
    de Winter-de Groot, Karin M.
    Clevers, Hans
    van der Ent, Cornelis K.
    Beekman, Jeffrey M.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (344)
  • [10] Novel opportunities for CFTR-targeting drug development using organoids
    Dekkers, Johanna F.
    van der Ent, Cornelis K.
    Beekman, Jeffrey M.
    [J]. RARE DISEASES, 2013, 1 (01)